Skip to content

Atracurium

Nondepolarizing Neuromuscular Blocker — MUSCULO-SKELETAL SYSTEM

Also known as: atracurium besylate, tracrium

OfpFDA approvedATC M03AC04

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Atracurium is an ofp drug in the Nondepolarizing Neuromuscular Blocker class catalogued in DrugCentral. It was first approved by the FDA in 1983. DrugCentral lists 6 molecular targets, including CHRNA3, CHRNA7 and CHRNA4. Recorded indications include General anesthesia, Muscle relaxation, function and Skeletal Muscle Relaxation for Endotracheal Intubation.

  • Approval status: ofp (first approved 1983 by the FDA).
  • Drug class: Nondepolarizing Neuromuscular Blocker.
  • Molecular targets: CHRNA3, CHRNA7, CHRNA4 and CHRNA1|CHRNB1|CHRND (6 listed in DrugCentral).
  • Indications: General anesthesia, Muscle relaxation, function and Skeletal Muscle Relaxation for Endotracheal Intubation.
  • ATC code: M03AC04 (Other quaternary ammonium compounds).
  • Molecular formula: C53H72N2O12; molecular weight 929.16 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

  • General anesthesia
  • Muscle relaxation, function
  • Skeletal Muscle Relaxation for Endotracheal Intubation

Contraindications (10)

  • Disorder of electrolytes
  • Disorder of lung
  • Eaton-Lambert syndrome
  • Hypermagnesemia
  • Hypocalcemia
  • Hypokalemia
  • Hypothermia
  • Low blood pressure
  • Malignant hyperthermia
  • Myasthenia gravis

Mechanism & targets

Established pharmacologic classNondepolarizing Neuromuscular Blocker

Molecular targets (6)

TargetGeneActionActivity
Neuronal acetylcholine receptor subunit alpha-3CHRNA3antagonistIC50 9.05
Neuronal acetylcholine receptor subunit alpha-7CHRNA7antagonistIC50 8.25
Neuronal acetylcholine receptor subunit alpha-4CHRNA4antagonistIC50 8.10
Acetylcholine receptorCHRNA1|CHRNB1|CHRNDantagonistIC50 7.77
Small conductance calcium-activated potassium channel protein 3Kcnn3unknownKi 5.23
Neuronal acetylcholine receptor subunit alpha-2CHRNA2unknown—

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
1983-11-23FDA——

ATC classification

ATC codeTherapeutic hierarchy
M03AC04MUSCULO-SKELETAL SYSTEM › MUSCLE RELAXANTS › MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS › Other quaternary ammonium compounds

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Anaphylactic shock1572.5
Anaphylactic reaction631.0
Bronchospasm436.5
Hypotension320.5
Mental status changes postoperative222.6
Cardiac arrest190.6
Circulatory collapse130.6
Eosinophilia117.1
Wrong product administered106.6
Bradycardia100.8
Tachycardia98.2
Rash maculo-papular93.3

Chemical structure

Molecular formulaC53H72N2O12
Molecular weight929.16 g/mol
CAS number64228-79-1
InChIKeyYXSLJKQTIDHPOT-UHFFFAOYSA-N
PubChem CID47319
COC1=C(OC)C=C(CC2C3=CC(OC)=C(OC)C=C3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCC3=CC(OC)=C(OC)C=C3C2CC2=CC(OC)=C(OC)C=C2)C=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Atracurium used for?

DrugCentral lists the following indications for Atracurium: General anesthesia, Muscle relaxation, function and Skeletal Muscle Relaxation for Endotracheal Intubation.

How does Atracurium work?

Its molecular targets in DrugCentral include CHRNA3 (antagonist), CHRNA7 (antagonist), CHRNA4 (antagonist) and CHRNA1|CHRNB1|CHRND (antagonist).

When was Atracurium first approved?

Atracurium was first approved by the FDA in 1983.

What drug class does Atracurium belong to?

Atracurium is in the Nondepolarizing Neuromuscular Blocker class.

What is the chemical formula of Atracurium?

Atracurium has the molecular formula C53H72N2O12 and a molecular weight of 929.16 g/mol.

Browse: all drugs starting with A · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFP
First approval1983-11-23
AgencyFDA
Targets6
Indications3
FormulaC53H72N2O12
DrugCentral ID259
Interactive profile